(Q34411257)

English

Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west (English)

1 reference

Europe PubMed Central

2 August 2017

neuropathic pain

0 references

1 reference

based on heuristic

inferred from title

author name string

Setsuro Ogawa

1

1 reference

Europe PubMed Central

2 August 2017

Jo Satoh

2

1 reference

Europe PubMed Central

2 August 2017

Akio Arakawa

3

1 reference

Europe PubMed Central

2 August 2017

Tamotsu Yoshiyama

4

1 reference

Europe PubMed Central

2 August 2017

Makoto Suzuki

5

1 reference

Europe PubMed Central

2 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2012

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

35

1 reference

Europe PubMed Central

2 August 2017

10

1 reference

Europe PubMed Central

2 August 2017

793-806

1 reference

Europe PubMed Central

2 August 2017

https://scigraph.springernature.com/pub.10.1007/bf03261976

0 references

Pregabalin pharmacology and its relevance to clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Clinical pharmacokinetics of pregabalin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Herpes zoster (shingles) and postherpetic neuralgia

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Variations in BMI and prevalence of health risks in diverse racial and ethnic populations

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FBF03261976

21 January 2018

Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22967187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database

1 reference

https://pubmed.ncbi.nlm.nih.gov/22967187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A questionnaire for neurological symptoms in patients with diabetes--cross-sectional multicenter study in Saitama Prefecture, Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/22967187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of diabetic neuropathy and neuropathic pain: how far have we come?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22967187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF03261976

1 reference

Europe PubMed Central

2 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34411257&oldid=1873589759"